Literature DB >> 16786388

[Nucleolysis in the herniated disk].

T Lehnert1, S Mundackatharappel, W Schwarz, S Bisdas, A Wetter, C Herzog, J O Balzer, M G Mack, T J Vogl.   

Abstract

Back pain associated with a herniated disk has become an important and increasing general health problem in Germany and other industrialized countries. After all methods of conservative treatment have been exhausted, nucleolysis may be a minimally invasive alternative to surgery. In nucleolysis, chondrolytic substances or other substances, which reduce the pressure within the disk by other means, are injected into the nucleus pulposus under CT guidance. Among various substances, which have been employed for nucleolysis, an ozone-oxygen mixture appears to be very promising. The water-binding capacity of ozone results in a reduction of pain for several months. Moreover, it has an anti-inflammatory effect and results in an increase of perfusion. Ozone is converted into pure oxygen in the body and has a low allergic potential. Recent minimally invasive therapeutic methods such as percutaneous nucleotomy or laser treatment do not result in superior results compared with nucleolysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786388     DOI: 10.1007/s00117-006-1379-2

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  29 in total

Review 1.  [Chemonucleolysis. Development, experiences, prospects].

Authors:  R Steffen; R von Bremen-Kühne
Journal:  Orthopade       Date:  1999-07       Impact factor: 1.087

2.  Effects of chondroitinase ABC on intradiscal pressure in sheep: an in vivo study.

Authors:  M Sasaki; T Takahashi; K Miyahara
Journal:  Spine (Phila Pa 1976)       Date:  2001-03-01       Impact factor: 3.468

3.  Chemonucleolysis versus discectomy: a randomized multicenter trial.

Authors:  H A van Alphen; R Braakman; P D Bezemer; G Broere; M W Berfelo
Journal:  J Neurosurg       Date:  1989-06       Impact factor: 5.115

4.  [Treatment of lumbar disk hernia by intra-disk injection of chymopapain or triamcinolone hexacetonide. Comparative study of 80 cases].

Authors:  D Bontoux; M Alcalay; F Debiais; O Garrouste; P Ingrand; I Azais; G Roualdes
Journal:  Rev Rhum Mal Osteoartic       Date:  1990-04-25

5.  Double-blind evaluation of chemonucleolysis for herniated lumbar discs. Late results.

Authors:  A N Martins; A Ramirez; J Johnston; P R Schwetschenau
Journal:  J Neurosurg       Date:  1978-12       Impact factor: 5.115

6.  The fate of chymopapain injected for therapy of intervertebral disc disease.

Authors:  A A Kapsalis; I J Stern; I Bornstein
Journal:  J Lab Clin Med       Date:  1974-04

7.  Intradiscal pressure after repeat intradiscal injection of hypertonic saline: an experimental study.

Authors:  Kimiaki Sato; Kensei Nagata; Teruyuki Hirohashi
Journal:  Eur Spine J       Date:  2002-02       Impact factor: 3.134

8.  Safety and efficacy of chymopapain (Discase) in the treatment of sciatica due to a herniated nucleus pulposus. Results of a randomized, double-blind study.

Authors:  E J Dabezies; K Langford; J Morris; C B Shields; H A Wilkinson
Journal:  Spine (Phila Pa 1976)       Date:  1988-05       Impact factor: 3.468

9.  A randomized, double-blind study to compare low-dose with standard-dose chymopapain in the treatment of herniated lumbar intervertebral discs.

Authors:  M Benoist; J F Bonneville; B Lassale; M Runge; C Gillard; J Vazquez-Suarez; A Deburge
Journal:  Spine (Phila Pa 1976)       Date:  1993-01       Impact factor: 3.468

10.  Chemonucleolysis with calpain I in rabbits.

Authors:  S Wakita; K Shimizu; K Suzuki; Y Nakagawa; S Yamamoto; T Yamamuro
Journal:  Spine (Phila Pa 1976)       Date:  1993-01       Impact factor: 3.468

View more
  1 in total

1.  Diffusion-Weighted Imaging for Pretreatment Evaluation and Prediction of Treatment Effect in Patients Undergoing CT-Guided Injection for Lumbar Disc Herniation.

Authors:  Xiang-Ke Niu; Anup Bhetuwal; Han-Feng Yang
Journal:  Korean J Radiol       Date:  2015-07-01       Impact factor: 3.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.